Obtained enormous global visibility and tremendous response from the authors and readers from all over the world inspired the publisher to maintain reputed Open Access Journals in various scientific disciplines. The journals have over 15 million readers and the reputation and success earned can be attributed to the strong Editorial Board which contains over 50, eminent personalities that ensure a rapid, qualitative and quick review process. More than International Societies are supporting in making scientific information Open Access.
ABEO Abeona Therapeutics is a clinical-stage biopharmaceutical company developing cell and gene therapies for life-threatening rare genetic diseases. In addition, Abeona is developing a proprietary vector platform, AIM, for next generation product candidates.
The company also has a T-cell program partnered with GSK, which has already shown preliminary evidence of tumor reduction in patients with synovial sarcoma and multiple myeloma. ADVM Adverum is a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases.
Adverum has a robust pipeline that includes product candidates designed to treat rare diseases alpha-1 antitrypsin deficiency and Hereditary Angioedema as well as wet age-related macular degeneration.
Leveraging a next-generation adeno-associated virus AAV -based directed evolution platform, Adverum generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein.
Adverum has collaboration agreements with Regeneron Pharmaceuticals to research, develop and commercialize gene therapy products for ophthalmic diseases, and Editas Medicine to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases.
In April of the U. AGTC AGTC is a clinical-stage biotechnology company that uses a proprietary gene therapy platform to develop transformational genetic therapies for Advantages of integrating biotechnology and genetic engineering in agriculture suffering from rare and debilitating diseases.
In addition to its product pipeline, AGTC has a significant intellectual property portfolio and extensive expertise in the design of gene therapy products including capsids, promoters and expression cassettes, as well as expertise in the formulation, manufacture and physical delivery of gene therapy products.
Preclinical animal studies demonstrate high efficacy in primary tumors and an abscopal effect in remote tumors. This cure has been preliminarily confirmed during pilot runs of HIV patient blood. AGT has also developed a synthetic gene that is capable of expressing therapeutic levels of human phenylalanine hydroxylase PAH to cure Phenylketonuria PKU that is expected to reach the clinic in ATRA Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases.
Atara is also developing off-the-shelf, allogeneic ATA and autologous ATA T-cell immunotherapies using a complementary targeted antigen recognition technology for specific EBV antigens believed to be important for the potential treatment of multiple sclerosis MS.
ATHX Athersys is an international biotechnology company engaged in the development of therapeutic products designed to extend and enhance the quality of human life.
The company is especially focused on disease indications in the neurological, cardiovascular and inflammatory and immune disease areas, and other critical care indications.
Food and Drug Administration. Their partner, Healios KK, is also conducting a parallel registrational trial in Japan. BTX BioTime is a clinical-stage biotechnology company focused on degenerative diseases.
Its clinical programs are based on two platform technologies: With its cell replacement platform, BioTime is producing new cells and tissues with its proprietary pluripotent cell technologies. These cells and tissues are developed to replace those that are either rendered dysfunctional or lost due to degenerative diseases or injuries.
BLUE With its lentiviral-based gene therapies, T-cell immunotherapy expertise and gene editing capabilities, bluebird bio has built an integrated product platform with broad potential application to severe genetic diseases and cancer.
Utilizing these cell therapies to replace damaged or degenerated tissue brings the potential to restore or regenerate lost function. The B-MoGen team is equipped with proprietary tools and knowledge that have been developed into finely honed methods for efficient cellular engineering.
The company utilizes this unique expertise to provide three distinct services that address highly complex gene delivery and gene editing.
They offer a non-viral transposon-based gene delivery platform to support the T-cell immunotherapy industry; they are the first company in the world to demonstrate genome engineering of the mitochondria genome; and they offer fee-for-service custom cell engineering of both cell lines and, uniquely, primary human lymphohematopoietic cells for cancer research, drug screening and antibody validation.
CLBS Caladrius Biosciences is a clinical-stage development company with cell therapy products in development based on multiple technology platforms and targeting cardiovascular and autoimmune indications.
Its late stage cardiovascular cell therapy targeting refractory angina recently received Regenerative Medicine Advanced Therapy RMAT designation and its critical limb ischemia program received Sakigake status in Japan. Capricor is also exploring the potential of CAP, a cell-free, extracellular vesicle-based candidate, to treat a variety of disorders.
We have two products in development. Our lead product, romyelocel-L, is a universal cell therapy to prevent infections during prolonged neutropenia. Our second product, CLT is an antibody-drug conjugate in preclinical development to treat AML by targeting and killing leukemic stem cells, which are believed to be the cause of relapse in patients.
CLT is directed at the C-type lectin-like molecule-1 CLL1which is highly expressed on leukemic stem cells, but not on normal hematopoietic stem or progenitor cells. Cell Medica has developed a business platform that has positioned the company as a leader in the manufacture and commercialization of cellular products.
The company collaborates with leading academic institutions to turn early stage innovations into medicinal products. With patient benefits at the forefront of their activities, the company has overcome the considerable challenges through collaboration and the will to succeed.
CYP Cynata Therapeutics is an Australian clinical-stage stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus, originating from the University of Wisconsin-Madison, a world leader in stem cell research. The proprietary Cymerus technology addresses a critical shortcoming in existing methods of production of multi-donor derived mesenchymal stem cells MSCs for therapeutic use, which is the ability to achieve consistent, economic manufacture at commercial scale.AGTC Sue Washer, President and CEO Oct.
4 | am | La Jolla Ballroom 2 Alachua, FL (NASDAQ: AGTC) AGTC is a clinical-stage biotechnology company that uses a proprietary gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases.
The first reason is the largest oil and gas company in the world, Exxon-Mobil, has commited the largest amount of money of any oil and gas firm in an R&D collaborative with Synthetic Genomics to leverage genetic pioneer Craig Venter’s knowledge of applied science in molecular engineering.”.
In the medicine field, gene therapy (also called human gene transfer) is the therapeutic delivery of nucleic acid into a patient's cells as a drug to treat disease. The first attempt at modifying human DNA was performed in by Martin Cline, but the first successful nuclear gene transfer in humans, approved by the National Institutes of Health, was performed in May Golden Rice is back in the news.
The Philippines and Bangladesh are moving closer towards commercialization of the GMO food crop to combat vitamin A deficiency, a .
Prospective inbound mobility students can browse through the list of undergraduate courses available at UTM for the UTM Student Exchange Program below. Plant biotechnology can be defined in many ways, but it is most often the genetic engineering of plants through the use of recombinant DNA.
This chapter focuses on regulatory requirements for genetically engineered (GE) plants.
Millions of people have already consumed the products of genetic engineering and no adverse effects have been reported or demonstrated. Integrating crop rotation and ecology with biotechnology is not only feasible but also the logical way to progress. V.W. (). Biotechnology and agriculture: A skeptical perspective. AgBioForum, 2(1. The second edition of Comprehensive Biotechnology continues the tradition of the first inclusive work on this dynamic field with up-to-date and essential entries on the principles and practice of biotechnology. The integration of the latest relevant science and industry practice with fundamental biotechnology concepts is presented with entries from internationally recognized world leaders in. Genetic engineering differs from conventional methods of genetic modification in two major ways: (1) genetic engineering introduces one or a few well-characterized genes into a plant species and (2) genetic engineering can introduce genes from any species into a plant.